505 related articles for article (PubMed ID: 26147615)
1. Cerebrospinal fluid biomarkers for Alzheimer's disease: current limitations and recent developments.
Zetterberg H
Curr Opin Psychiatry; 2015 Sep; 28(5):402-9. PubMed ID: 26147615
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer's disease--Recent biomarker developments in relation to updated diagnostic criteria.
Höglund K; Fourier A; Perret-Liaudet A; Zetterberg H; Blennow K; Portelius E
Clin Chim Acta; 2015 Sep; 449():3-8. PubMed ID: 25668231
[TBL] [Abstract][Full Text] [Related]
3. CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42.
Andreasen N; Sjögren M; Blennow K
World J Biol Psychiatry; 2003 Oct; 4(4):147-55. PubMed ID: 14608585
[TBL] [Abstract][Full Text] [Related]
4. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.
Shaw LM; Vanderstichele H; Knapik-Czajka M; Figurski M; Coart E; Blennow K; Soares H; Simon AJ; Lewczuk P; Dean RA; Siemers E; Potter W; Lee VM; Trojanowski JQ;
Acta Neuropathol; 2011 May; 121(5):597-609. PubMed ID: 21311900
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer's Disease-Associated Cerebrospinal Fluid (CSF) Biomarkers do not Correlate with CSF Volumes or CSF Production Rate.
Edsbagge M; Andreasson U; Ambarki K; Wikkelsø C; Eklund A; Blennow K; Zetterberg H; Tullberg M
J Alzheimers Dis; 2017; 58(3):821-828. PubMed ID: 28505972
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers for Alzheimer's disease: current status and prospects for the future.
Blennow K; Zetterberg H
J Intern Med; 2018 Dec; 284(6):643-663. PubMed ID: 30051512
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology.
Blennow K; Chen C; Cicognola C; Wildsmith KR; Manser PT; Bohorquez SMS; Zhang Z; Xie B; Peng J; Hansson O; Kvartsberg H; Portelius E; Zetterberg H; Lashley T; Brinkmalm G; Kerchner GA; Weimer RM; Ye K; Höglund K
Brain; 2020 Feb; 143(2):650-660. PubMed ID: 31834365
[TBL] [Abstract][Full Text] [Related]
9. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
[TBL] [Abstract][Full Text] [Related]
10. Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer's disease.
Mouton-Liger F; Paquet C; Dumurgier J; Lapalus P; Gray F; Laplanche JL; Hugon J;
Biol Psychiatry; 2012 May; 71(9):829-35. PubMed ID: 22281122
[TBL] [Abstract][Full Text] [Related]
11. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
Doecke JD; Rembach A; Villemagne VL; Varghese S; Rainey-Smith S; Sarros S; Evered LA; Fowler CJ; Pertile KK; Rumble RL; Trounson B; Taddei K; Laws SM; Macaulay SL; Bush AI; Ellis KA; Martins R; Ames D; Silbert B; Vanderstichele H; Masters CL; Darby DG; Li QX; Collins S;
J Alzheimers Dis; 2018; 61(1):169-183. PubMed ID: 29171991
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
[TBL] [Abstract][Full Text] [Related]
14. Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive.
Oláh Z; Kálmán J; Tóth ME; Zvara Á; Sántha M; Ivitz E; Janka Z; Pákáski M
J Alzheimers Dis; 2015; 44(4):1303-12. PubMed ID: 25428253
[TBL] [Abstract][Full Text] [Related]
15. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's Disease.
Pan C; Korff A; Galasko D; Ginghina C; Peskind E; Li G; Quinn J; Montine TJ; Cain K; Shi M; Zhang J
J Alzheimers Dis; 2015; 45(3):709-19. PubMed ID: 25613100
[TBL] [Abstract][Full Text] [Related]
18. Concordance of Lumipulse cerebrospinal fluid t-tau/Aβ42 ratio with amyloid PET status.
Kaplow J; Vandijck M; Gray J; Kanekiyo M; Huyck E; Traynham CJ; Esquivel R; Fagan AM; Luthman J
Alzheimers Dement; 2020 Jan; 16(1):144-152. PubMed ID: 31914216
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols.
Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Giau VV; Bagyinszky E; Lim KT; Kang SM; An SS; Park YH; Youn YC; Kim S
J Alzheimers Dis; 2016 May; 52(4):1403-13. PubMed ID: 27163824
[TBL] [Abstract][Full Text] [Related]
20. Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.
Mattsson N; Lönneborg A; Boccardi M; Blennow K; Hansson O;
Neurobiol Aging; 2017 Apr; 52():196-213. PubMed ID: 28317649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
